View in EDS

Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.

Saved in:
Bibliographic Details
Title: Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.
Authors: Alho AC; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA; Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal;, Kim HT; Department of Biostatistics and Computational Biology, and Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA; and Harvard Chan School of Public Health, Boston, MA., Chammas MJ; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA;, Reynolds CG; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA;, Matos TR; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA;, Forcade E; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA;, Whangbo J; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA;, Nikiforow S; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA;, Cutler CS; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA;, Koreth J; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA;, Ho VT; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA;, Armand P; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA;, Antin JH; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA;, Alyea EP; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA;, Lacerda JF; Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal;, Soiffer RJ; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA;, Ritz J; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA; Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA; and.
Source: Blood [Blood] 2016 Feb 04; Vol. 127 (5), pp. 646-57. Date of Electronic Publication: 2015 Dec 15.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1528-0020
DOI:10.1182/blood-2015-10-672345